title: Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.
abstract: The HIV antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) was recently approved as preexposure prophylaxis (PrEP) therapy for adults at high risk for sexually acquired HIV infection. This article reviews the data supporting the efficacy of PrEP, and provides other relevant data regarding the implementation of PrEP.
authors.affiliation: Christopher W. Blackwell is an associate professor and coordinator of Nurse Practitioner Programs at University of Central Florida, College of Nursing, Orlando, Fla.
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Blackwell
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000379:methods*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D009943:Organophosphorus Compounds; D003841:Deoxycytidine